Vanda Pharmaceuticals Inc.
General ticker "VNDA" information:
- Sector: Health Care
- Industry: Biotechnology
- Capitalization: $352.0M (TTM average)
Vanda Pharmaceuticals Inc. follows the US Stock Market performance with the rate: 23.3%.
Estimated limits based on current volatility of 2.9%: low 5.41$, high 5.73$
Factors to consider:
- Earnings expected soon, date: 2026-07-30 bmo
- Total employees count: 533 (+44.8%) as of 2025
- Countries other than US accounted for 5.0% of revenue in the fiscal year ended 2024-12-31
- Top business risk factors: Dependence on product success, FDA safety and review issues, Regulatory and compliance, Third-party risks, Economic downturns and volatility
- Price in estimated range
- Earnings for 3 months up through Q1 are below our estimates
Stock Forecast*
* forecast is subjective and experimental, should not be used for any investment decisions
Long term estimates were made for the period from 2025-12-31 to 2027-12-31
- 2025-12-31 to 2026-12-31 estimated range: [4.89$, 10.14$]
- 2026-12-31 to 2027-12-31 estimated range: [4.21$, 8.95$]
Financial Metrics affecting the VNDA estimates:
- Positive: with PPE of -4.0 at the end of fiscal year the price was neutral
- Negative: negative Operating cash flow
- Negative: negative Operating income
- Positive: Interest expense per share per price, % of 0 <= 0.01
- Positive: Investing cash flow per share per price, % of 22.64 > -0.60
- Negative: negative Net income
- Positive: Inventory ratio change, % of -0.01 <= 0
- Positive: Shareholder equity ratio, % of 66.92 > 64.23
Short-term VNDA quotes
Long-term VNDA plot with estimates
Financial data
| YTD | 2023-12-31 | 2024-12-31 | 2025-12-31 |
|---|---|---|---|
| Operating Revenue | $192.64MM | $198.77MM | $216.10MM |
| Operating Expenses | $206.59MM | $239.43MM | $367.27MM |
| Operating Income | $-13.95MM | $-40.66MM | $-151.17MM |
| Non-Operating Income | $20.29MM | $17.74MM | $12.52MM |
| R&D Expense | $76.82MM | $74.43MM | $109.27MM |
| Income(Loss) | $6.34MM | $-22.92MM | $-138.65MM |
| Taxes | $3.83MM | $-4.02MM | $81.83MM |
| Net Income(Loss)* | $2.51MM | $-18.90MM | $-220.47MM |
| Stockholders Equity | $544.91MM | $538.55MM | $327.19MM |
| Inventory | $1.36MM | $1.73MM | $1.85MM |
| Assets | $648.44MM | $656.20MM | $488.95MM |
| Operating Cash Flow | $12.80MM | $-15.76MM | $-109.44MM |
| Capital expenditure | $0.38MM | $0.49MM | $1.00MM |
| Investing Cash Flow | $-12.06MM | $-17.43MM | $94.86MM |
| Financing Cash Flow | $0.00MM | $-0.15MM | $-2.91MM |
| Earnings Per Share** | $0.04 | $-0.33 | $-3.74 |
* Profit(Loss) attributable to entity.
** EPS are Split Adjusted, recent splits may be reflected with a delay.